M SD’s oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has succeeded in a third Phase III trial in ...

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The 470,000ft² facility is set to bolster the company's biologics and ...

MSD’s NDA is supported by week 48 data from two Phase III trials, MK-8591A-051 and MK-8591A-052.

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Parrott said one of MSD's major obstacles to pursuing its 20-year plan is the consent decree it entered into with state and federal agencies in 2005 to solve the longstanding problem of sewer ...